Marina Karp has been named to the newly created role, tasked with helping develop CHPA’s health policy priorities and engage stakeholders regarding the value of OTCs, dietary supplements and consumer medical devices, the organization said.
Pfizer and GlaxoSmithKline have closed their joint venture to combine their respective consumer healthcare businesses and form the world’s largest over-the-counter business. This new venture will operate as the new GSK Consumer Healthcare.
The company named John Salley its executive vice president of marketing, effective immediately, and tasked him with helping market Leading Edge Pharms’ Cananvera line of CBD-based topical pain and inflammation products.
New data from the Consumer Healthcare Products Association and IRI is highlighting the ripple effect that a consumer buying an OTC product can have on the American healthcare system — namely, some $146 billion in savings.
GlaxoSmithKline will have a controlling 68% equity interest and Pfizer will have a 32% equity interest in the joint venture, which would have a global OTC market share of 7.3%, leading the market in most key geographical areas, including the United States and China.